ETF Movers on Wednesday: TAN and NUGO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy DXCM?
Source: NASDAQ.COM
ETF Performance: The Nuveen Growth Opportunities ETF is underperforming, down approximately 2.1% in Wednesday afternoon trading.
Weakest Components: Key contributors to the ETF's decline include Arista Networks, which fell by about 6.9%, and Dexcom, which decreased by about 3.3%.
Market Context: The article highlights the performance of specific ETFs and their components, indicating broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 61.540
Low
68.00
Averages
82.54
High
100.00
Current: 61.540
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Outlook for Healthcare Tech Companies
- TransMedics Growth Potential: TransMedics Group's Organ Care System (OCS) significantly enhances organ storage and transport efficiency by mimicking human physiology, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Strategy: TransMedics plans to launch the OCS for kidneys to further expand its market, while aggressively expanding in Europe, enhancing its market opportunities, which is expected to drive performance growth over the next decade.
- Dexcom's Market Leadership: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue last year, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing its strong performance in diabetes management.
- Technological Innovation and Market Expansion: Dexcom not only leads the market among diabetes patients but also enters the over-the-counter market with the launch of Stelo, which is expected to attract more potential users and further enhance its long-term growth prospects.
See More
TransMedics and Dexcom's Market Prospects
- TransMedics Innovation: TransMedics Group's Organ Care System (OCS) mimics human physiology to significantly enhance organ storage and transport efficiency, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Opportunities: TransMedics plans to launch the OCS for kidneys to further expand its market coverage, while aggressive expansion in Europe is expected to enhance its market opportunities, driving performance growth over the next decade.
- Dexcom's Sustained Growth: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing strong performance in diabetes management.
- Untapped Market Potential: Despite concerns over the popularity of GLP-1 weight loss drugs, Dexcom's management emphasizes that physicians prescribe CGM devices alongside these therapies, and the vast global market remains largely untapped, promising long-term returns for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm promises to handle cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing the financial burden and encouraging more shareholders to participate.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately increases shareholder value and has significant strategic implications.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
See More
DexCom (DXCM) Q2 2025 Earnings Call Transcript
See More
DexCom Announces Q1 2026 Financial Results Release Plan
- Earnings Release Schedule: DexCom plans to release its Q1 2026 financial results after market close on April 30, 2026, highlighting the company's ongoing innovation and development in diabetes management.
- Conference Call Details: Management will hold a conference call at 4:30 PM (Eastern Time) on the same day to review the first quarter performance, which is expected to attract significant attention from investors and analysts.
- Webcast Support: The conference call will be concurrently webcast, allowing investors to access the information through DexCom's investor relations website, ensuring transparency and accessibility of information.
- Company Background: Founded in 1999, DexCom has pioneered glucose biosensing technology for over 25 years, dedicated to empowering individuals to manage diabetes more effectively and improve their quality of life.
See More
DEXCOM STOCK RISES 0.4% FOLLOWING EVERCORE ISI UPGRADE TO OUTPERFORM FROM IN LINE
Stock Performance: Dexcom shares increased by 0.4% following a positive earnings report.
Earnings Report Impact: The rise in stock price was attributed to a strong performance from the company's core business.
See More
Investment Outlook for Healthcare Tech Companies
- TransMedics Growth Potential: TransMedics Group's Organ Care System (OCS) significantly enhances organ storage and transport efficiency by mimicking human physiology, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Strategy: TransMedics plans to launch the OCS for kidneys to further expand its market, while aggressively expanding in Europe, enhancing its market opportunities, which is expected to drive performance growth over the next decade.
- Dexcom's Market Leadership: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue last year, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing its strong performance in diabetes management.
- Technological Innovation and Market Expansion: Dexcom not only leads the market among diabetes patients but also enters the over-the-counter market with the launch of Stelo, which is expected to attract more potential users and further enhance its long-term growth prospects.
See More
TransMedics and Dexcom's Market Prospects
- TransMedics Innovation: TransMedics Group's Organ Care System (OCS) mimics human physiology to significantly enhance organ storage and transport efficiency, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Opportunities: TransMedics plans to launch the OCS for kidneys to further expand its market coverage, while aggressive expansion in Europe is expected to enhance its market opportunities, driving performance growth over the next decade.
- Dexcom's Sustained Growth: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing strong performance in diabetes management.
- Untapped Market Potential: Despite concerns over the popularity of GLP-1 weight loss drugs, Dexcom's management emphasizes that physicians prescribe CGM devices alongside these therapies, and the vast global market remains largely untapped, promising long-term returns for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm promises to handle cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing the financial burden and encouraging more shareholders to participate.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately increases shareholder value and has significant strategic implications.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
See More
DexCom (DXCM) Q2 2025 Earnings Call Transcript
See More
DexCom Announces Q1 2026 Financial Results Release Plan
- Earnings Release Schedule: DexCom plans to release its Q1 2026 financial results after market close on April 30, 2026, highlighting the company's ongoing innovation and development in diabetes management.
- Conference Call Details: Management will hold a conference call at 4:30 PM (Eastern Time) on the same day to review the first quarter performance, which is expected to attract significant attention from investors and analysts.
- Webcast Support: The conference call will be concurrently webcast, allowing investors to access the information through DexCom's investor relations website, ensuring transparency and accessibility of information.
- Company Background: Founded in 1999, DexCom has pioneered glucose biosensing technology for over 25 years, dedicated to empowering individuals to manage diabetes more effectively and improve their quality of life.
See More
DEXCOM STOCK RISES 0.4% FOLLOWING EVERCORE ISI UPGRADE TO OUTPERFORM FROM IN LINE
Stock Performance: Dexcom shares increased by 0.4% following a positive earnings report.
Earnings Report Impact: The rise in stock price was attributed to a strong performance from the company's core business.
See More
